Cardiovascular Prevention and Pharmacotherapy

Special Article

Shifting from Pharmacotherapy to Prevention of Hypertension: Bernard Man Yung Cheung, Man-Fung Tsoi; Cardiovasc Prev Pharmacother. 2020;2(2):33-42. Published online April 30, 2021; DOI: https://doi.org/10.36011/cpp.2020.2.e8

9,448 View
43 Download
1 Citations

Hypertension is a common chronic disease affecting a large section of the general population. As hypertension is usually asymptomatic, awareness, treatment and control rates are low. Drug side-effects also affect compliance. Hypotension and electrolyte abnormalities in the elderly can be severe. Therefore, prevention is better than cure. As blood pressure rises with age, prevention should be started early. As there are many genes affecting blood pressure, genetic tests are not useful. Good antenatal care and care of preterm infants can help to prevent adult cardiovascular diseases including hypertension. Childhood obesity is an important determinant of blood pressure in childhood and adolescence. This is a window of opportunity for prevention. The current American College of Cardiology/American Heart Association guideline on hypertension defines stage 1 hypertension as a systolic blood pressure of 130–139 mmHg or a diastolic blood pressure of 80–89 mmHg. Although this makes many people in the general population hypertensive, stage 1 hypertension in young adults is already associated with increased cardiovascular and mortality risk. Fortunately, hypertension at this early stage is easy to control and weight loss is easier in young males, who can get exercise from work or exercise after work. Leisure-time physical activity seems more beneficial than occupational physical activity. Cardiovascular risk assessment and promoting a healthy lifestyle in the young are likely to forestall hypertension and future cardiovascular disease. Preventing or reversing hypertension is no longer an impossible dream.

Citations

Citations to this article as recorded by

The Association Between Dietary Inflammatory Index (DII) and Risk of Hypertension: A Case–Control Study
Niloofar Shoaei, Nafiseh Shokri-Mashhadi, Awat feizi, Reza Ghiasvand
High Blood Pressure & Cardiovascular Prevention.2022; 29(6): 611. CrossRef

Review Article

Prevention of Type 2 Diabetes: Jong Dai Kim, Won-Young Lee; Cardiovasc Prev Pharmacother. 2020;2(3):63-76. Published online July 31, 2020; DOI: https://doi.org/10.36011/cpp.2020.2.e10

12,719 View
119 Download
1 Citations

Abstract PDF

The number of patients with type 2 diabetes (T2D) is increasing worldwide and that in Korea, particularly, has shown an exponential increase with a rise in the older population. The diabetic population is predicted to soar up to 6 million by 2050. The prevalence of diabetes among Korean adults is approximately 15%, while that of prediabetes is 25%, with a total prevalence of 40%. As 40% of the prediabetes cases subsequently progress to T2D, prevention through proactive interventions at the prediabetes stage is essential to reduce the socioeconomic burden due to T2D and the complications of diabetes. With regard to the prevention of T2D, new findings have been published related to the implementation of lifestyle interventions such as exercise and diet as well as drug treatments and surgeries, which have deepened our understanding of the prevention of T2D. Based on published evidence, this review aimed to examine the methods used in the prevention of diabetes.

Citations

Citations to this article as recorded by

Diabetes-specific oral nutritional supplement for prediabetes improves postprandial glycemic responses: an open-label, crossover clinical trial
Yeongtaek Hwang, Minkyung Bok, Suk Chon, Hyunjung Lim
Nutrition Research and Practice.2025; 19(6): 904. CrossRef

First
Prev
Page of 1
Next
Last

Search